NVS logo

Novartis AG

NVS
Healthcare|Drug Manufacturers - General|CH
$162.55
+0.62 (+0.38%)
DCF Value
$269.57
Graham Number
$48.20
Cash / Share
$4.75

Financials

Financial Snapshot

Market Cap
$307.00B
Enterprise Value
$345.79B
Revenue (TTM)
$56.31B
Net Income (TTM)
$10.03B
Cash & Investments
$8.97B
Net Cash
-$39.34B
Free Cash Flow (TTM)
$14.84B
Operating CF (TTM)
$17.32B
Debt/Equity
1.30

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$7.78B$9.48B$15.96B$11.45B$11.56B$28.11B$18.61B$13.96B$13.35B$11.59B$8.97B
Operating Cash Flow
$11.47B$12.62B$14.27B$13.63B$13.65B$15.07B$14.24B$14.46B$17.62B$19.24B$17.32B
Free Cash Flow
$8.60B$9.88B$10.92B$11.37B$11.06B$12.52B$12.00B$11.71B$13.80B$17.69B$14.84B
Capital Expenditure
-$2.88B-$2.75B-$3.35B-$2.26B-$2.58B-$2.56B-$2.24B-$2.75B-$3.81B-$1.56B-$2.48B
Financing Cash Flow
-$5.31B-$7.73B-$4.24B-$13.63B-$2.21B-$16.26B-$20.56B-$14.28B-$11.74B-$14.94B$797.2M

R&D Spending

R&D (TTM)
$13.49B
R&D Intensity
24.0%
R&D Growth vs Prior
+25.5%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$49.44B$43.40B$46.10B$48.68B$49.90B$43.97B$43.46B$46.66B$51.72B$54.81B$56.31B
R&D Expense
$9.04B$8.39B$8.49B$9.40B$8.98B$8.64B$9.17B$11.37B$10.02B$10.74B$13.49B
R&D % of Revenue
18.3%19.3%18.4%19.3%18.0%19.7%21.1%24.4%19.4%19.6%24.0%
SG&A
$14.19B$12.46B$13.72B$14.37B$14.20B$12.83B$12.19B$12.52B$12.57B$13.31B$12.90B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$49.44B$43.40B$46.10B$48.68B$49.90B$43.97B$43.46B$46.66B$51.72B$54.81B$56.31B
Cost of Revenue
$17.52B$13.63B$14.51B$14.43B$15.12B$11.73B$11.58B$12.47B$12.83B$13.69B$14.29B
Gross Profit
$31.92B$29.77B$31.59B$34.25B$34.78B$32.24B$31.88B$34.19B$38.90B$41.12B$42.02B
R&D
$9.04B$8.39B$8.49B$9.40B$8.98B$8.64B$9.17B$11.37B$10.02B$10.74B$13.49B
SG&A
$14.19B$12.46B$13.72B$14.37B$14.20B$12.83B$12.19B$12.52B$12.57B$13.31B$12.90B
Operating Income
$8.27B$8.70B$8.40B$9.09B$10.15B$10.06B$7.95B$9.77B$14.54B$17.07B$14.33B
Interest Expense
$729.0M$802.0M$973.2M$902.9M$921.0M$905.0M$834.6M$876.1M$1.04B$1.19B$1.58B
Pretax Income
$7.82B$9.10B$14.10B$8.94B$9.88B$24.53B$7.18B$9.12B$13.64B$16.44B$12.65B
Net Income
$6.71B$7.70B$12.61B$11.73B$8.07B$24.02B$6.96B$14.85B$11.94B$14.06B$10.03B
EPS (Diluted)
2.803.255.383.083.5210.633.177.105.877.195.24
EBITDA
$14.57B$14.59B$20.24B$15.62B$17.21B$30.91B$14.68B$18.25B$20.71B$22.99B$21.78B
Shares Out. (M)
2400.002371.002344.002319.002296.002260.002197.002092.002035.001955.001905.00

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$7.01B$8.86B$13.27B$11.11B$9.66B$12.41B$7.52B$13.39B$11.46B$11.44B$8.87B
Short-Term Investments
$770.0M$625.0M$2.69B$334.0M$1.91B$15.71B$11.10B$569.0M$1.89B$155.0M$105.0M
Total Current Assets
$24.93B$28.21B$35.56B$29.50B$29.67B$45.72B$36.91B$30.48B$29.70B$30.46B$28.75B
Total Assets
$130.12B$133.08B$145.56B$118.41B$132.19B$131.79B$117.45B$99.94B$102.25B$115.57B$117.15B
Total Current Liabilities
$22.21B$23.40B$29.61B$28.26B$33.06B$30.21B$28.66B$26.39B$28.69B$27.28B$32.52B
Long-Term Debt
$17.90B$23.22B$22.47B$20.35B$26.26B$22.90B$20.24B$18.44B$21.37B$29.59B$36.70B
Total Liabilities
$55.23B$58.85B$66.87B$62.86B$75.52B$63.97B$58.03B$53.20B$58.12B$69.02B$79.58B
Stockholders' Equity
$74.83B$74.17B$78.61B$55.47B$56.60B$67.66B$59.34B$46.67B$44.05B$46.13B$37.23B
Retained Earnings
$81.15B$77.64B$82.19B$59.27B$57.16B$70.99B$63.54B$49.65B$46.56B$44.72B$39.24B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$11.47B$12.62B$14.27B$13.63B$13.65B$15.07B$14.24B$14.46B$17.62B$19.24B$17.32B
Capital Expenditure
-$2.88B-$2.75B-$3.35B-$2.26B-$2.58B-$2.56B-$2.24B-$2.75B-$3.81B-$1.56B-$2.48B
Free Cash Flow
$8.60B$9.88B$10.92B$11.37B$11.06B$12.52B$12.00B$11.71B$13.80B$17.69B$14.84B
Investing Cash Flow
-$3.44B-$3.12B-$5.59B-$2.23B-$13.18B$4.21B$1.47B$5.60B-$7.51B-$4.90B-$18.68B
Financing Cash Flow
-$5.31B-$7.73B-$4.24B-$13.63B-$2.21B-$16.26B-$20.56B-$14.28B-$11.74B-$14.94B$797.2M
Issuance of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$27.1M$18.0M
Repurchase of Stock
-$1.11B-$5.49B-$2.04B-$5.53B-$2.84B-$3.06B-$10.65B-$8.72B-$8.33B-$9.26B-$6.25B
Net Debt Issuance
$2.06B$4.10B$4.18B-$4.96B$7.07B-$5.67B-$2.58B-$1.94B$4.39B$2.72B$16.33B
Stock Based Comp.
$671.0M$683.0M$759.0M$758.0M$738.0M$700.0M$791.0M$865.0M$1.04B$0.00$570.0M
Net Change in Cash
$2.33B$1.85B$4.41B-$2.16B-$1.45B$2.75B-$4.89B$5.88B-$1.93B-$24.0M-$685.9M

Dilution Tracker

Shares Outstanding
1889M
5-Year Share Growth
-14.9%
Stock Issuance (TTM)
$18.0M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
2400.002371.002344.002319.002296.002260.002197.002092.002035.001955.001905.00
Change vs Prior %
—-1.2%-1.1%-1.1%-1.0%-1.6%-2.8%-4.8%-2.7%-3.9%-2.6%
Stock Issuance
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$27.1M$18.0M
Stock Repurchase
-$1.11B-$5.49B-$2.04B-$5.53B-$2.84B-$3.06B-$10.65B-$8.72B-$8.33B-$9.26B-$6.25B
Stock Based Comp.
$671.0M$683.0M$759.0M$758.0M$738.0M$700.0M$791.0M$865.0M$1.04B$0.00$570.0M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
64.6%68.6%68.5%70.4%69.7%73.3%73.4%73.3%75.2%75.0%74.6%
Operating Margin %
16.7%20.0%18.2%18.7%20.3%22.9%18.3%20.9%28.1%31.2%25.5%
Net Margin %
13.6%17.7%27.4%24.1%16.2%54.6%16.0%31.8%23.1%25.6%17.8%
EBITDA Margin %
29.5%33.6%43.9%32.1%34.5%70.3%33.8%39.1%40.1%41.9%38.7%
FCF Margin %
17.4%22.8%23.7%23.4%22.2%28.5%27.6%25.1%26.7%32.3%26.4%
ROE %
9.0%10.4%16.0%21.1%14.3%35.5%11.7%31.8%27.1%30.5%24.2%
ROA %
5.2%5.8%8.7%9.9%6.1%18.2%5.9%14.9%11.7%12.2%8.4%
ROIC %
6.1%6.2%6.1%7.5%7.6%8.7%7.1%11.5%15.5%15.5%14.0%
R&D / Revenue %
18.3%19.3%18.4%19.3%18.0%19.7%21.1%24.4%19.4%19.6%24.0%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
-1.9%-12.2%6.2%5.6%2.5%-11.9%-1.2%7.4%10.8%6.0%
Gross Profit
-3.2%-6.7%6.1%8.4%1.5%-7.3%-1.1%7.2%13.8%5.7%
Operating Income
-7.9%5.2%-3.4%8.1%11.7%-0.9%-21.0%22.9%48.9%17.4%
Net Income
-62.3%14.8%63.7%-7.0%-31.2%197.6%-71.0%113.5%-19.6%17.7%
EPS (Diluted)
-61.6%16.1%65.5%-42.8%14.3%202.0%-70.2%124.0%-17.3%22.5%
Operating Cash Flow
-3.5%10.0%13.1%-4.5%0.2%10.4%-5.5%1.6%21.9%9.2%
Free Cash Flow
6.8%14.9%10.6%4.1%-2.7%13.1%-4.1%-2.4%17.9%28.1%
R&D Expense
1.2%-7.2%1.2%10.8%-4.5%-3.8%6.1%24.0%-11.9%7.2%
SG&A Expense
-0.4%-12.2%10.0%4.8%-1.2%-9.6%-4.9%2.7%0.4%5.9%
Total Assets
-1.1%2.3%9.4%-18.7%11.6%-0.3%-10.9%-14.9%2.3%13.0%
Book Value / Share
-1.9%0.5%7.2%-28.5%2.6%21.5%-9.9%-17.4%-2.9%9.8%
Debt
8.5%19.4%12.9%-9.2%29.9%-18.0%-10.0%-5.6%18.6%18.5%
Diluted Shares
-1.6%-1.2%-1.1%-1.1%-1.0%-1.6%-2.8%-4.8%-2.7%-3.9%

Valuation

P/E (TTM)31.18
10Y Low / Med / High7.73 / 21.42 / 28.72
P/S5.57
10Y Low / Med / High2.93 / 4.22 / 4.88
P/B8.22
10Y Low / Med / High1.94 / 3.60 / 5.79
EV/EBITDA15.39
10Y Low / Med / High6.61 / 12.64 / 14.30
EV/Revenue6.29
10Y Low / Med / High3.27 / 4.64 / 5.34
P/FCF19.96
10Y Low / Med / High14.23 / 16.69 / 18.39

Intrinsic Value Models (per share)

DCF Value
$269.57
Graham Number
$48.20
Cash / Share
$4.75
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
21.6121.4213.2028.7225.247.7326.9114.1216.4419.0231.18
P/S Ratio
2.933.803.614.224.084.224.314.493.804.885.57
P/B Ratio
1.942.222.123.703.602.743.164.494.465.798.22
EV/EBITDA
11.1012.649.1614.3013.466.6114.1412.2010.4412.7415.39
EV/Revenue
3.274.254.024.594.644.644.784.774.185.346.29

Analyst Estimates & Quality

Altman Z-Score
3.63
Safe
Piotroski F-Score
7
Strong

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$57.19B$61.01B$64.79B
Net Income$17.33B$19.27B$21.10B
EPS$8.86$9.86$10.79
# Analysts (EPS)686

Dividends

Dividend/Share (TTM)
$4.51
Dividend Yield
2.78%
Frequency
Annual

Recent Payments

Ex-DatePay DateAmountFrequency
Mar 11, 2026Mar 16, 2026$4.74Annual
Mar 12, 2025Apr 25, 2025$3.99Annual
Mar 7, 2024Apr 19, 2024$3.20Annual
Mar 9, 2023Mar 20, 2023$3.50Annual
Mar 8, 2022Mar 17, 2022$3.33Annual
Mar 4, 2021Mar 15, 2021$3.20Annual
Mar 3, 2020Mar 12, 2020$3.09Annual
Mar 4, 2019Mar 13, 2019$2.57Annual
Mar 6, 2018Apr 25, 2018$2.67Annual
Mar 1, 2017Apr 20, 2017$2.46Annual
Feb 24, 2016Apr 15, 2016$2.47Annual
Mar 2, 2015Apr 20, 2015$2.52Annual
Feb 27, 2014Apr 10, 2014$2.72Annual
Feb 26, 2013Apr 5, 2013$2.27Annual
Feb 27, 2012Apr 5, 2012$2.20Annual
Feb 24, 2011Apr 8, 2011$2.36Annual
Mar 2, 2010Apr 13, 2010$1.95Annual
Feb 24, 2009Apr 6, 2009$1.54Annual
Feb 26, 2008Apr 11, 2008$1.54Annual
Mar 6, 2007Apr 10, 2007$0.97Annual

Revenue Segments

By Product

Segment20182019202020212022
Top 20 products$26.95B$28.65B$29.92B$32.66B$32.14B
Rest of portfolio$7.95B$9.07B$9.10B$9.33B$9.16B
COPD—$427.0M———
Anti Infectives sold under Sandoz name—$784.0M$694.0M$707.0M$777.0M
Total anti-infectives net sales———$1.10B$1.20B

By Geography

Segment20182019202020212022
Country of domicile$852.0M—$800.0M$873.0M$970.0M
FRANCE$2.71B$2.44B$2.44B$2.52B$2.26B
GERMANY$4.18B$4.12B$4.52B$4.87B$4.28B
JAPAN$3.17B$2.66B$2.80B$2.68B$2.21B
Other countries$22.17B—$19.04B$20.81B$20.05B
UNITED STATES$17.56B$16.28B$16.48B$16.82B$17.65B
CHINA——$2.57B$3.05B$3.13B